Ruti Aga's Six-Year Ban: A Forged Prescription, a Missing Clinic, and the Medical-Governance Gap

The clinic address on the prescription did not exist. The signature belonged to a family member, not a medically registered doctor. The family member said the prescription had been written on an old pad from a former workplace; the clinic said the pad was not theirs. That piece of paper was supposed to document a knee injection for Ruti Aga. It became the heaviest document in her six-year ban.

The Athletics Integrity Unit said in a statement released on Thursday that the 32-year-old Ethiopian marathon runner had been banned for six years for the presence of methylprednisolone and for submitting a forged prescription. She had been provisionally suspended since 10 September, and the ban was also dated from 10 September. The statement did not give the time she ran at the March half marathon in China where the sample was collected. It did not give the year the ban would end. Those numbers cannot be invented.

Aga's name was not built by this case alone. She won the 2026 Tokyo Marathon. She has three second-place finishes at World Marathon Majors. Her competitive class is usually placed in the 2:18 to 2:20 range, although the source report does not list her personal best. She won a half marathon in China in March, and the sample taken after that race contained methylprednisolone. She said she had a knee injury and had received an injection. The AIU found that the prescription was fake.

The case then splits into two parts. One is about a medicine. The other is about a document. A large section of the media called it a steroid case. That description is technically loose. Methylprednisolone is a glucocorticoid, not an anabolic steroid. It sits in class S9 of the WADA Prohibited List, and under the current List S9 glucocorticoids are prohibited in-competition only, by injection, oral or rectal routes. That detail changes the legal hinge of the case. The question is not whether she took a steroid. The question is by which route, at what time, and on what medical basis the medicine was given.

I have spent years reading Indian athletics result sheets. In 2026, when the calendar stopped and the Gujarat State Athletics Association office in Ahmedabad was closed, I scanned 2,400 result sheets and built a searchable database. Two thousand four hundred result sheets, and an office door that stayed closed. That work taught me a habit: in any story, first ask which document exists, which document is missing, and who chose not to keep it. In Aga's case, the missing document is the real medical record. The document that exists is the forged prescription. That gap turns a doping notice into a governance story.

There is no lane in this column, and no name beside the time. The result sheet from the March half marathon will have a time on it. The AIU statement does not. I will not infer her form from the fact that she won. What is known is that she won and was tested. What is unknown is her time, her splits, the strength of the field and the status of the race. Without those, saying she was in good form would be guesswork, not reporting.

Two years and four years: the arithmetic of the sanction

The structure that emerges from the AIU statement is clear: two years for the presence violation and four years for tampering. Six years in total. That arithmetic is itself evidence. It shows the case was not only about a positive sample. If the case had been confined to the medicine, the shape of the sanction would have been different. The separate four-year penalty shows the panel treated the forged document as an independent and serious violation.

Under the WADA Code and World Athletics anti-doping rules, tampering is a separate offence. It covers submitting false documents, misleading an investigation or interfering with evidence. In Aga's case the charge was not confined to paper. The AIU investigation also took in her statements. That is why the tampering sanction reached four years.

The important point is that the two-year presence sanction did not come with the mitigation that a no-significant-fault argument can attract. If she had real medical records, a clear route and timing record, and a treatment plan tied to a Therapeutic Use Exemption, the presence charge might have had a legitimate defence. The forged prescription closed that route.

In standard AIU practice, the result and prize money from the competition where the sample was collected are liable to disqualification. The statement does not spell out the scope. It does not say which earlier results, if any, are affected. The general principle is that results after the established violation date are affected; older results are not automatically annulled without separate proof of earlier use. So the 2026 Tokyo Marathon title should not be treated as automatically erased. But the statement does not clarify this either.

Records check: the report does not give the year of the March race, the time, the end date of the ban or the list of annulled results. Without those four items, the picture is incomplete. The reader needs to see where the facts stop and inference begins.

What S9 means: the medicine and the document

Calling methylprednisolone a steroid sounds right in ordinary conversation, but it creates confusion in sports law. Anabolic steroids are class S1. Glucocorticoids are class S9. The rationale for prohibition is different. Anabolic steroids are associated with muscle building and recovery. Glucocorticoids are used to suppress inflammation and pain. In a marathon runner's knee, they are a common sports-medicine tool.

Under the current WADA List, S9 glucocorticoids are prohibited in-competition only, and only by injection, oral or rectal routes. An injection given out-of-competition is not automatically a violation. A violation arises when the substance is present in-competition, or when the athlete uses a prohibited route without a TUE. In road races the in-competition period is generally taken to begin at 23:59 the day before the race. An injection given days earlier can therefore be caught if residues remain.

This is the key to the case. If Aga received an injection for a knee injury out-of-competition, with a proper medical entry, there was a legitimate defence. If she had a TUE, the defence was stronger. If there was enough time between the injection and the race, that could have been argued. The forged prescription pushed all those questions in one direction: if the treatment was real, why was the paper fake?

That is the uncomfortable part. An athlete can be injured. An athlete can lack proper medical advice. People around an athlete can make a bad decision. But when the prescription is written by a family member with no medical registration, when the clinic address does not exist, and when the clinic disowns the old pad, three separate verifications fail. The doctor's identity fails. The clinic's existence fails. The document's source fails. Three failures together are not a filing error. They are a picture of a medical system that exists on paper, not in practice.

The knee, the pain and the economics of the marathon

A marathon runner's knee is the weakest part of the career. A body running 150 to 200 kilometres a week carries load through the joint for 42 kilometres. Chronic inflammation, cartilage wear and patellar tendon trouble are ordinary experiences. A glucocorticoid injection is one of the fastest ways to relieve pain and reduce swelling. It can allow an athlete to run.

That relief is also the warning. Less pain does not mean the injury has healed. A runner who masks pain can make the damage worse. Medical governance is therefore not only about which medicine was taken. It is about who gave it, who observed it, who recorded it and who decided the athlete was fit to race.

In Ethiopian road running, athletes are often managed through agents, coaches and small camps. Not every athlete has a full medical team. Treatment can be informal. In that environment, the right drug and the right paper both matter. Without paper, the athlete has only her word. If that word is reinforced with a fake document, the case becomes weaker.

Aga is 32. A six-year ban keeps her out until about 38. A comeback at 38 is not impossible in women's marathon running, but against Ethiopian depth it is not a practical return. Ethiopia's women's marathon pool is world-record class. A 2:18 performer is not automatically selected. The ban is therefore not simply six years of absence. It is the end of a competitive life.

There is another layer. The 2026 Tokyo title and the three Major second places are part of a genuinely elite record. They do not automatically disappear. But commercially, she is now an athlete with a doping record attached to her name. Road-running sponsorship is thin. Appearance fees and prize money are a large part of income. A ban damages both.

The Chinese half marathon and the appearance-fee economy

The March half marathon in China is the geographical centre of the case. The AIU statement does not name the race or its label. But a race where the AIU collects a sample is not an ordinary local event. It has an elite women's field and in-competition testing. That connects the case to the economics of road racing.

For East African marathon runners, Asian label races are a separate income tier. There are only a few Majors each year. Between them, athletes go to races where appearance fees are good and recovery time is short. The half marathon is part of that model. It is shorter than a marathon but useful for income and visibility.

The other side of the model is AIU testing. Where there are large appearance fees, there is a large elite field. Where there is a large elite field, there is testing pressure. The appearance-fee economy and the testing economy now collide in the same races. Aga's case is one example.

Under standard AIU practice, the result from the testing race can be disqualified and prize money can be reclaimed. Ranking points can go as well. The statement does not spell this out. But if the standard process applies, the March win and its income are at risk. That is the economic side of the case that doping headlines often leave out.

Ethiopian depth and a career that becomes invisible

Ethiopia's strength in women's marathon running is depth. One athlete's removal does not measurably change the national team's capacity. That can feel cruel, but it is the structure of the sport. A 2:18 to 2:20 marathon runner would be a dream for many countries; in Ethiopia she can be on the edge of selection.

Aga's six-year ban therefore does not change Ethiopia's competitive strength. What it changes is the governance picture. Her case shows how weak the medical structure around an athlete can be. A family member writes a prescription as a doctor. A clinic exists on paper but not on the ground. An old prescription pad is used and then disowned. This is not only one athlete's story. It is the story of a system that did not give the athlete the right paper.

The AIU statement does not mention a response from the Ethiopian federation. It does not say whether an agent or management was investigated. Only the family member is named. That silence matters. When the people around an athlete are not held accountable, the penalty falls on the athlete alone.

The tampering era: investigation moves to documents

A pattern has emerged in recent AIU road-running cases. A positive sample comes first. Then the athlete or the circle around the athlete offers an explanation. Investigation shows the documentary basis is false. The case becomes about tampering as well as the substance. Aga's case appears to belong to that family.

The enforcement frontier is shifting. The sample used to be the centre. The document is now part of the centre. Is the prescription real? Is the doctor registered? Does the clinic exist? Whose pad is it? These questions now matter as much as the concentration in the sample. Anti-doping is moving from detection to verification.

That shift has a direct effect. Athletes without a strong medical team are more exposed. An athlete with a large team can produce the right paper, the right date and the right TUE. An athlete in a small camp can be trapped by informal treatment and weak paper. The inequality is real.

The penalty and the lesson: what six years buys

The easy story is that a marathon runner doped, forged a prescription and received six years. That is true, but incomplete. The harder story is that a glucocorticoid with no proven direct endurance benefit produced a six-year ban whose largest share came from the document. The price is less about the medicine than about the cover-up.

Was six years too much? The question will be asked from two directions. One side will say tampering is a separate offence and the penalty is standard. The other will say six years for a glucocorticoid looks heavier than many anabolic-steroid cases. Both arguments deserve a hearing. Legally, it would be wrong to say the sentence is only for the medicine. The separate four-year penalty shows the panel treated the forged prescription as an independent offence.

It is also necessary to be fair to Aga's record. Winning the 2026 Tokyo Marathon is not small. Three second places at World Marathon Majors are the results of a genuine elite runner. This case should not be turned into a story that erases her career. It should not be turned into a story of a helpless athlete either. Both can be true: she was an elite marathon runner, and she broke the rules.

The media description of the case as a steroid case is a professional error. Calling the substance by the wrong class leads readers to think this is a muscle-building case. It is an anti-inflammatory case in which route and timing are the legal centre. That carelessness blurs public understanding of anti-doping.

What India should take from this: paper, clinics and the road-running boom

India's road-running market has expanded quickly. Every large city has a half marathon, every season has new events, and every event has an elite category. Alongside that market has grown another thing: informal medical advice. Many runners take supplements through coaches, visit physios and use painkillers. Every case is not doping. But every case raises the same question: who holds the medical record?

Indian athletics has a particular feature. An athlete's career runs on performance and on a job. Railways, Services, police and PSU recruitment are the backbone of many careers. An injury is therefore not only a medical decision but an economic one. If an athlete believes an injection will return him to the track sooner, he may take the risk. That is where medical governance matters.

The lesson for India is not that every injection is suspicious. It is that the injection's paper, date, route and doctor's identity must be clear. State associations, SAI centres and railway medical teams should explain TUEs and in-competition periods in local languages. That work is as important as timing splits on the track.

I have an experience from the 2026 Khelo India School Games. In Delhi, while watching Ravi Solanki, Gujarat's only under-17 javelin finalist, I went to his coach Hasmukh Patel. Before I could ask about the throw, I had to ask who kept the record. The coach kept the splits in a notebook nobody asked to see. I went looking for a finalist and found the man who wrote everything down. That habit matters in Aga's case too. What was not written cannot defend you. What was written falsely can convict you.

What comes next: the question behind the closed door

Aga can appeal to the Court of Arbitration for Sport. There is usually a fixed window after the reasoned decision. An appeal looks unlikely to succeed because the main evidence is documentary. A fake prescription, an unregistered signature, a missing clinic and a disowned pad are hard to reverse together. An appeal could argue that the language or translation of her interview was unfair. That is a legitimate legal issue, but it would have to be shown to have affected the outcome.

The larger lesson is that anti-doping is no longer only a test of a sample. It is a test of a medical file. An athlete with no proper file can lose even when she is right. An athlete with a fake file can lose even on the medicine. That is the new reality.

One question remains unanswered: what was the role of the agent and management? The AIU statement names only the family member. If an agent helped create or accepted the fake prescription, accountability should reach that person too. An athlete should not carry the weight of an entire system alone.

Two things are clear looking ahead. More cases of this kind can surface in the Ethiopian and Kenyan road-racing circuits, because the same informal medical networks serve many athletes. And AIU investigations will now reach into prescriptions, pads and clinic addresses. That is the natural next step.

Somewhere between the headline and the margin, an athlete is standing. She has a win, an injury, an injection and a fake prescription. The next time a marathon runner receives a knee injection, the question will not only be what the medicine was. It will be who wrote the record, who hid it, and who made the paper so weak that it proved a lie instead of protecting the truth.